These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6968502)

  • 1. Altered deoxynucleoside triphosphate levels paralleling deoxyadenosine toxicity in adenosine deaminase inhibited human lymphocytes.
    Bluestein HG; Thompson LF; Albert DA; Seegmiller JE
    Adv Exp Med Biol; 1980; 122A():427-31. PubMed ID: 6968502
    [No Abstract]   [Full Text] [Related]  

  • 2. The mechanism of inhibition and "reversal" of mitogen-induced lymphocyte activation in a model of adenosine deaminase deficiency.
    Albert D; Bluestein HG; Thompson L; Seegmiller JE
    Cell Immunol; 1984 Jul; 86(2):510-7. PubMed ID: 6610485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase.
    Lee N; Russell N; Ganeshaguru K; Jackson BF; Piga A; Prentice HG; Foa R; Hoffbrand AV
    Br J Haematol; 1984 Jan; 56(1):107-19. PubMed ID: 6231047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
    Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
    J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanism of ATP catabolism induced by deoxyadenosine and other nucleosides in adenosine deaminase-inhibited human erythrocytes.
    Bontemps F; Van den Berghe G
    Adv Exp Med Biol; 1989; 253B():267-74. PubMed ID: 2558538
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of erythro-9-(2-hydroxy-3-nonyl) adenine on purine and pyrimidine metabolism in the human peripheral lymphocyte during the early phases of phytohemagglutinin-mediated blastogenesis.
    Skupp S; Vugrek G; Ayvazian JH
    Biochem Pharmacol; 1979 Nov; 28(22):3323-31. PubMed ID: 526339
    [No Abstract]   [Full Text] [Related]  

  • 7. Accumulation of deoxyribonucleotides as a possible mediator of immunosuppression in hereditary deficiency of adenosine deaminase.
    Bluestein HG; Willis RC; Thompson LF; Matsumoto S; Seegmiller JE
    Trans Assoc Am Physicians; 1978; 91():394-402. PubMed ID: 314193
    [No Abstract]   [Full Text] [Related]  

  • 8. Activated T lymphocytes resist the toxic effects of the adenosine deaminase inhibitor, 2-deoxycoformycin.
    Kotb M; Veit BC
    Cell Immunol; 1982 Sep; 72(1):64-76. PubMed ID: 6983389
    [No Abstract]   [Full Text] [Related]  

  • 9. Enhancement of the biological activity of cordycepin (3'-deoxyadenosine) by the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johns DG; Adamson RH
    Biochem Pharmacol; 1976 Jun; 25(12):1441-4. PubMed ID: 1084747
    [No Abstract]   [Full Text] [Related]  

  • 10. Deoxy-ATP accumulation in adenosine deaminase-inhibited human B and T lymphocytes.
    Gruber HE; Cohen AH; Firestein GS; Redelman D; Bluestein HG
    Adv Exp Med Biol; 1986; 195 Pt A():503-7. PubMed ID: 3487921
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.
    Bagnara AS; Hershfield MS
    Proc Natl Acad Sci U S A; 1982 Apr; 79(8):2673-7. PubMed ID: 6283540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inability of poly-ADP-ribosylation inhibitors to protect peripheral blood lymphocytes from the toxic effects of ADA inhibition.
    Ganeshaguru K; Piga A; Latini L; Hoffbrand AV
    Adv Exp Med Biol; 1989; 253B():251-8. PubMed ID: 2532859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of lymphocyte-specific enzymes: a promising approach for selective immunosuppression.
    Ruers TJ; Buurman WA; van der Linden CJ; Kootstra G
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1287-9. PubMed ID: 3274319
    [No Abstract]   [Full Text] [Related]  

  • 14. Toxicities of adenosine and 2'-deoxyadrenosine in L cells treated with inhibitors of adenosine deaminase.
    Lapi L; Cohen SS
    Biochem Pharmacol; 1977 Jan; 26(1):71-6. PubMed ID: 299815
    [No Abstract]   [Full Text] [Related]  

  • 15. Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes.
    Bontemps F; Van den Berghe G
    Cancer Res; 1989 Sep; 49(18):4983-9. PubMed ID: 2788493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase.
    Carson DA; Wasson DB; Lakow E; Kamatani N
    Proc Natl Acad Sci U S A; 1982 Jun; 79(12):3848-52. PubMed ID: 6808516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA repair in nondividing human lymphocytes: inhibition by deoxyadenosine.
    Cohen A; Thompson E
    Cancer Res; 1986 Apr; 46(4 Pt 1):1585-8. PubMed ID: 3485013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for purine metabolism in the immune response: Adenosine-deaminase activity and deoxyadenosine catabolism.
    Simmonds HA; Panayi GS; Corrigall V
    Lancet; 1978 Jan; 1(8055):60-3. PubMed ID: 74565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purine deoxynucleoside toxicity in nondividing human lymphoid cells.
    Kefford RF; Fox RM
    Cancer Res; 1982 Jan; 42(1):324-30. PubMed ID: 6976204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of adenosine deaminase and the development of antiviral agents.
    Cohen SS
    Ann N Y Acad Sci; 1985; 451():204-14. PubMed ID: 2416257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.